FDA Takes New Regulatory Action Against Ranbaxy’s Paonta Sahib Plant in India

Feb. 25, 2009--The U.S. FDA today announced that a facility owned by India-based Ranbaxy Laboratories falsified data and test results in approved and pending drug applications. The facility, Paonta Sahib, has been under an FDA Import Alert since September 2008.

the details can be read here.